NeuroSense Therapeutics effects 1-for-20 reverse stock split on Sept. 14, 2026
NRSN•Reverse stock split details
NeuroSense Therapeutics will execute a 1-for-20 reverse stock split of its ordinary shares.
Post-split trading on the Nasdaq Capital Market is set to begin on Sept. 14, 2026.
Issued shares are expected to fall to 1,896,902 from 37,938,036, subject to rounding of fractional shares.
Fractional shares will be rounded up to the nearest whole share.
Outstanding warrants and options will be adjusted proportionately for share count and exercise price.
